1887

Journal of General Virology header logo

Volume 98, Issue 3

Recombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal delivery Open Access

Abstract

We have previously established that mucosal uptake of recombinant fowlpox virus (rFPV) vaccines is far superior to other vector-based vaccines. Specifically, intranasal priming with rFPV vaccines can recruit unique antigen-presenting cells, which induce excellent mucosal and systemic HIV-specific CD8 T-cell immunity. In this study, we have for the first time investigated the dissemination, safety and expression kinetics of rFPV post intranasal delivery using recombinant viruses expressing green fluorescent protein or mCherry. Both confocal microscopy of tissue sections using green fluorescent protein and Imaging System (IVIS) spectrum live animal and whole organ imaging studies using mCherry revealed that (i) the peak antigen expression occurs 12 to 24 h post vaccination and no active viral gene expression is detected 96 h post vaccination. (ii) The virus only infects the initial vaccination site (lung and nasal cavity) and does not disseminate to distal sites such as the spleen or gut. (iii) More importantly, rFPV does not cross the olfactory receptor neuron pathway. Collectively, our findings indicate that rFPV vector-based vaccines have all the hallmarks of a safe and effective mucosal delivery vector, suitable for clinical evaluation.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): expression kinetics , Fowlpox virus vectors , GFP , HIV vaccines , intranasal , IVIS spectrum live animal imaging , mCherry and safety
© 2017 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000702
2017-03-01
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/3/496.html?itemId=/content/journal/jgv/10.1099/jgv.0.000702&mimeType=html&fmt=ahah

References

  1. Afonso CL, Tulman ER, Lu Z, Zsak L, Kutish GF et al. The genome of fowlpox virus. J Virol 2000; 74:3815–3831 [View Article][PubMed]
     [Google Scholar]
  2. Skinner MA, Laidlaw SM, Eldaghayes I, Kaiser P, Cottingham MG. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 2005; 4:63–76 [View Article][PubMed]
     [Google Scholar]
  3. Boyle DB, Coupar BE. Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Virus Res 1988; 10:343–356 [View Article][PubMed]
     [Google Scholar]
  4. Taylor J, Weinberg R, Languet B, Desmettre P, Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 1988; 6:497–503 [View Article][PubMed]
     [Google Scholar]
  5. Dale CJ, De Rose R, Wilson KM, Croom HA, Thomson S et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNγ or IL-12. Vaccine 2004; 23:188–197 [View Article][PubMed]
     [Google Scholar]
  6. Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 2005; 23:5009–5021 [View Article][PubMed]
     [Google Scholar]
  7. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 2003; 9:2973–2980[PubMed]
     [Google Scholar]
  8. Somogyi P, Frazier J, Skinner MA. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 1993; 197:439–444 [View Article][PubMed]
     [Google Scholar]
  9. Nelson JB. The behavior of pox viruses in the respiratory tract: IV. The nasal instillation of fowl pox virus in chickens and in mice. J Exp Med 1941; 74:203–212 [View Article][PubMed]
     [Google Scholar]
  10. Weli SC, Nilssen O, Traavik T. Avipoxvirus multiplication in a mammalian cell line. Virus Res 2005; 109:39–49 [View Article][PubMed]
     [Google Scholar]
  11. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997; 238:198–211 [View Article][PubMed]
     [Google Scholar]
  12. Kelleher AD, Puls RL, Bebbington M, Boyle D, Ffrench R et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. Aids 2006; 20:294–297 [View Article][PubMed]
     [Google Scholar]
  13. Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One 2011; 6:e27837 [View Article][PubMed]
     [Google Scholar]
  14. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005; 102:4836–4841 [View Article][PubMed]
     [Google Scholar]
  15. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203:610–619 [View Article][PubMed]
     [Google Scholar]
  16. Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 2007; 25:2863–2885 [View Article][PubMed]
     [Google Scholar]
  17. Corbett M, Bogers WM, Heeney JL, Gerber S, Genin C et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci USA 2008; 105:2046–2051 [View Article][PubMed]
     [Google Scholar]
  18. Ranasinghe C, Eyers F, Stambas J, Boyle DB, Ramshaw IA et al. A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. Vaccine 2011; 29:3008–3020 [View Article][PubMed]
     [Google Scholar]
  19. Ranasinghe C, Medveczky JC, Woltring D, Gao K, Thomson S et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 2006; 24:5881–5895 [View Article][PubMed]
     [Google Scholar]
  20. Wijesundara DK, Ranasinghe C, Jackson RJ, Lidbury BA, Parish CR et al. Use of an in vivo FTA assay to assess the magnitude, functional avidity and epitope variant cross-reactivity of T cell responses following HIV-1 recombinant poxvirus vaccination. PLoS One 2014; 9:e105366 [View Article][PubMed]
     [Google Scholar]
  21. Ranasinghe C, Trivedi S, Stambas J, Jackson RJ. Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8+ T-cell avidity and protective immunity. Mucosal Immunol 2013; 6:1068–1080 [View Article][PubMed]
     [Google Scholar]
  22. Trivedi S, Jackson RJ, Ranasinghe C. Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity. Virology 2014; 468–470:479–489 [View Article][PubMed]
     [Google Scholar]
  23. Ranasinghe C, Turner SJ, Mcarthur C, Sutherland DB, Kim JH et al. Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 2007; 178:2370–2379 [View Article][PubMed]
     [Google Scholar]
  24. Belyakov IM, Wyatt LS, Ahlers JD, Earl P, Pendleton CD et al. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol 1998; 72:8264–8272[PubMed]
     [Google Scholar]
  25. Kozlowski PA, Neutra MR. The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 2003; 3:217–228[PubMed] [Crossref]
     [Google Scholar]
  26. Coupar BEH, Purcell DFJ, Thomson SA, Ramshaw IA, Kent SJ et al. Fowlpox virus vaccines for HIV and SIV clinical and pre-clinical trials. Vaccine 2006; 24:1378–1388 [View Article][PubMed]
     [Google Scholar]
  27. Lemiale F, Kong WP, Akyürek LM, Ling X, Huang Y et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003; 77:10078–10087 [View Article][PubMed]
     [Google Scholar]
  28. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896–903 [View Article][PubMed]
     [Google Scholar]
  29. Gómez CE, Nájera JL, Domingo-Gil E, Ochoa-Callejero L, González-Aseguinolaza G et al. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol 2007; 88:2473–2478 [View Article][PubMed]
     [Google Scholar]
  30. Ramirez JC, Finke D, Esteban M, Kraehenbuhl JP, Acha-Orbea H. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 2003; 148:827–839 [View Article][PubMed]
     [Google Scholar]
  31. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881–1893 [View Article][PubMed]
     [Google Scholar]
  32. Baxby D, Paoletti E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine 1992; 10:8–9 [View Article][PubMed]
     [Google Scholar]
  33. Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 2012; 8:1192–1207 [View Article][PubMed]
     [Google Scholar]
  34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209–2220 [View Article][PubMed]
     [Google Scholar]
  35. Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007; 44:203–212 [View Article][PubMed]
     [Google Scholar]
  36. Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007; 46:48–55 [View Article][PubMed]
     [Google Scholar]
  37. Zanotto C, Pozzi E, Pacchioni S, Volonté L, de Giuli Morghen C et al. Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison. Antiviral Res 2010; 88:53–63 [View Article][PubMed]
     [Google Scholar]
  38. Tulman ER, Afonso CL, Lu Z, Zsak L, Kutish GF et al. The genome of canarypox virus. J Virol 2004; 78:353–366 [View Article][PubMed]
     [Google Scholar]
  39. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998; 244:365–396 [View Article][PubMed]
     [Google Scholar]
  40. Falivene J, Del Médico Zajac MP, Pascutti MF, Rodríguez AM, Maeto C et al. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One 2012; 7:e32220 [View Article][PubMed]
     [Google Scholar]
  41. Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V et al. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 2012; 86:5026–5038 [View Article][PubMed]
     [Google Scholar]
  42. Puehler F, Schwarz H, Waidner B, Kalinowski J, Kaspers B et al. An interferon-gamma-binding protein of novel structure encoded by the fowlpox virus. J Biol Chem 2003; 278:6905–6911 [View Article][PubMed]
     [Google Scholar]
  43. Laidlaw SM, Skinner MA. Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of fowlpox virus, with those of virulent American and European viruses. J Gen Virol 2004; 85:305–322 [View Article][PubMed]
     [Google Scholar]
  44. Laidlaw SM, Robey R, Davies M, Giotis ES, Ross C et al. Genetic screen of a mutant poxvirus library identifies an ankyrin repeat protein involved in blocking induction of avian type I interferon. J Virol 2013; 87:5041–5052 [View Article][PubMed]
     [Google Scholar]
  45. Buttigieg K, Laidlaw SM, Ross C, Davies M, Goodbourn S et al. Genetic screen of a library of chimeric poxviruses identifies an ankyrin repeat protein involved in resistance to the avian type I interferon response. J Virol 2013; 87:5028–5040 [View Article][PubMed]
     [Google Scholar]
  46. Jackson RJ, Worley M, Trivedi S, Ranasinghe C. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy. Vaccine 2014; 32:5703–5714 [View Article][PubMed]
     [Google Scholar]
  47. Wong YC, Lin LC, Melo-Silva CR, Smith SA, Tscharke DC. Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection. J Virol Methods 2011; 171:295–298 [View Article][PubMed]
     [Google Scholar]
  48. Siemering KR, Golbik R, Sever R, Haseloff J. Mutations that suppress the thermosensitivity of green fluorescent protein. Curr Biol 1996; 6:1653–1663 [View Article][PubMed]
     [Google Scholar]
  49. Boyle DB, Anderson MA, Amos R, Voysey R, Coupar BE. Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules. Biotechniques 2004; 37:104–111[PubMed] [Crossref]
     [Google Scholar]
  50. Jackson RJ, Boyle DB, Ranasinghe C. Progresses in DNA-based heterologous prime-boost immunization strategies. Methods Mol Biol 2014; 1143:61–90 [View Article][PubMed]
     [Google Scholar]
  51. Coupar BE, Andrew ME, Boyle DB. A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. Gene 1988; 68:1–10 [View Article][PubMed]
     [Google Scholar]
  52. Heine HG, Boyle DB. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch Virol 1993; 131:277–292 [View Article][PubMed]
     [Google Scholar]
  53. Ravichandran J, Jackson RJ, Trivedi S, Ranasinghe C. IL-17A expression in HIV-specific CD8 T cells is regulated by IL-4/IL-13 following HIV-1 prime-boost immunization. J Interferon Cytokine Res 2015; 35:176–185 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000702
Loading
Recombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal delivery
J. Gen. Virol. 98, 496 (2017); https://doi.org/10.1099/jgv.0.000702
/content/journal/jgv/10.1099/jgv.0.000702
/content/journal/jgv/10.1099/jgv.0.000702
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error